Abstract
Myeloid-derived suppressor cells (MDSC) are believed to play a role in immune suppression and subsequent failure of T cells to mount an efficient anti-tumor response, by employing both direct T-cell inhibition as well as induction of regulatory T cells (Tregs). Investigating the frequency and function of immune suppressive cell subsets in the peripheral blood of 41 patients with prostate cancer (PC) and 36 healthy donors (HD) showed a significant increase in circulating CD14+ HLA-DRlow/neg monocytic MDSC (M-MDSC) and Tregs in patients with PC compared to HD. Furthermore, M-MDSC frequencies correlated positively with Treg levels. In vitro proliferation assay with autologous T cells confirmed M-MDSC-mediated T-cell suppression, and intracellular staining of immune suppressive enzyme iNOS revealed a higher expression in M-MDSC from patients with PC. Increased frequencies of M-MDSC correlated with known negative prognostic markers in patients with PC including elevated levels of lactate dehydrogenase and prostate-specific antigen. Accordingly, high levels of M-MDSC were associated with a shorter median overall survival. Our data strongly suggest that M-MDSC, possibly along with Tregs, play a role in establishing an immune suppressive environment in patients with PC. Moreover, correlation of M-MDSC frequency with known prognostic markers and the observed impact on OS could reflect a possible role in tumor progression. Further insight into the generation and function of MDSC and their interplay with Tregs and other cell types may suggest ways to tackle their induction and/or function to improve immunological tumor control.
Similar content being viewed by others
References
Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131. doi:10.1200/JCO.2009.24.2180
Carvalhal GF, Daudi SN, Kan D et al (2010) Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology 76:1072–1076. doi:10.1016/j.urology.2009.11.056
Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094. doi:10.1200/JCO.2005.04.5252
Kantoff PW, Schuetz TJ, Blumenstein Ba et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099–1105. doi:10.1200/JCO.2009.25.0597
Rigamonti N, Bellone M (2012) Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother 61:453–468. doi:10.1007/s00262-012-1216-6
Filipazzi P, Valenti R, Huber V et al (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546–2553. doi:10.1200/JCO.2006.08.5829
Poschke I, Kiessling R (2012) On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 144:250–268. doi:10.1016/j.clim.2012.06.003
Bronte V, Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641–654. doi:10.1038/nri1668
Habibi D, Jalili RB, Forouzandeh F et al (2010) High expression of IMPACT protein promotes resistance to indoleamine 2,3-dioxygenase-induced cell death. J Cell Physiol 225:196–205. doi:10.1002/jcp.22220
Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. doi:10.1038/nri2506
Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804–811. doi:10.1182/blood-2006-02-002774
Gustafson MP, Lin Y, New KC et al (2010) Systemic immune suppression in glioblastoma: the interplay between CD14+ HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 12:631–644. doi:10.1093/neuonc/noq001
Kalathil S, Lugade Aa, Miller A et al (2013) Higher Frequencies of GARP+ CTLA-4+ Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-Cell functionality. Cancer Res 73:2435–2444. doi:10.1158/0008-5472.CAN-12-3381
Ko JS, Zea AH, Rini BI et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148–2157. doi:10.1158/1078-0432.CCR-08-1332
Hoechst B, Gamrekelashvili J, Manns MP et al (2011) Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 117:6532–6541. doi:10.1182/blood-2010-11-317321
Liu W, Putnam AL, Xu-Yu Z et al (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203:1701–1711. doi:10.1084/jem.20060772
Riley CH, Jensen MK, Brimnes MK et al (2011) Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood 118:2170–2173. doi:10.1182/blood-2011-03-340992
Halabi S, Lin C-Y, Kelly WK et al (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32:671–677. doi:10.1200/JCO.2013.52.3696
Bronte V, Wang M, Overwijk WW et al (1998) Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 161:5313–5320
Walter S, Weinschenk T, Stenzl A et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261. doi:10.1038/nm.2883
Vuk-Pavlović S, Bulur Pa, Lin Y et al (2010) Immunosuppressive CD14+ HLA-DRlow/- monocytes in prostate cancer. Prostate 70:443–455. doi:10.1002/pros.21078
Brusa D, Simone M, Gontero P et al (2013) Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int J Urol 20:971–978. doi:10.1111/iju
Filipazzi P, Huber V, Rivoltini L (2012) Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61:255–263. doi:10.1007/s00262-011-1161-9
Kotsakis A, Harasymczuk M, Schilling B et al (2012) Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 381:14–22. doi:10.1016/j.jim.2012.04.004
Poschke I, Mougiakakos D, Hansson J et al (2010) Immature immunosuppressive CD14+ HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70:4335–4345. doi:10.1158/0008-5472.CAN-09-3767
Ramachandran IR, Martner A, Pisklakova A et al (2013) Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 190:3815–3823. doi:10.4049/jimmunol.1203373
Rodriguez PC, Zea AH, Culotta KS et al (2002) Regulation of T cell receptor CD3zeta chain expression by l-arginine. J Biol Chem 277:21123–21129. doi:10.1074/jbc.M110675200
Whiteside TL (2004) Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865–878. doi:10.1007/s00262-004-0521-0
Bronte V, Kasic T, Gri G et al (2005) Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201:1257–1268. doi:10.1084/jem.20042028
Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL (2002) Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br J Cancer 86(2):168–178
Afonso G, Scotto M, Renand A et al (2010) Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms. J Immunol Methods 359:28–36. doi:10.1016/j.jim.2010.05.005
Derhovanessian E, Adams V, Hähnel K et al (2009) Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 125:1372–1379. doi:10.1002/ijc.24497
Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759–767. doi:10.1002/ijc.25429
Hoechst B, Ormandy LA, Ballmaier M et al (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135:234–243. doi:10.1053/j.gastro.2008.03.020
Mougiakakos D, Choudhury A, Lladser A et al (2010) Regulatory T cells in cancer. Adv Cancer Res 107:57–117. doi:10.1016/S0065-230X(10)07003-X
Gregg R, Smith CM, Clark FJ et al (2005) The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol 140:540–546. doi:10.1111/j.1365-2249.2005.02798.x
Verschoor CP, Johnstone J, Millar J et al (2013) Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 93:633–637. doi:10.1189/jlb.0912461
Yuan X-K, Zhao X-K, Xia Y-C et al (2011) Increased circulating immunosuppressive CD14+ HLA-DR-/low cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res 39:1381–1391. doi:10.1177/147323001103900424
Diaz-Montero CM, Salem ML, Nishimura MI et al (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59. doi:10.1007/s00262-008-0523-4
Arihara F, Mizukoshi E, Kitahara M et al (2013) Increase in CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 62:1421–1430. doi:10.1007/s00262-013-1447-1
Azevedo A, Cunha V, Teixeira AL, Medeiros R (2011) IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2:384–396. doi:10.5306/wjco.v2.i12.384
Wu C-T, Hsieh C–C, Lin C–C et al (2012) Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med 90:1343–1355. doi:10.1007/s00109-012-0916-x
Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061. doi:10.1126/science.1079490
Kleinewietfeld M, Starke M, Di Mitri D et al (2009) CD49d provides access to “untouched” human Foxp3+ Treg free of contaminating effector cells. Blood 113:827–836. doi:10.1182/blood-2008-04-150524
Weide B, Martens A, Zelba H et al (2014) Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or Melan-A-specific T cells. Clin Cancer Res 20:1601–1609. doi:10.1158/1078-0432.CCR-13-2508
Acknowledgments
The authors thank Kirsten Nikolajsen for technical support and Tobias Wirenfeldt Klausen for assistance with the statistical analyses. Grants from the Danish Cancer Society, The Danielsen Foundation, and Toyota Fonden funded the study.
Conflict of interest
None of the authors have any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Idorn, M., Køllgaard, T., Kongsted, P. et al. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 63, 1177–1187 (2014). https://doi.org/10.1007/s00262-014-1591-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-014-1591-2